Product Information
METHYLPHENIDATE ER 30 MG CAP is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $2.8775 per EA under NDC 42858007845. Its NADAC has been published 165 times since Dec 21, 2022.
FDA first approved this application on Apr 17, 2015. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858007845
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
2/19/2025
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA205831FDA Approved
4/17/2015
TE Code
AB3
On Market Since
4/1/2020
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE ER 30 MG CAP has been published 165 times since Dec 21, 2022, and over the history we have for it it has declined 42.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.8775 per EA |
|---|---|
| All-time high | $5.5319 (Apr 10, 2024) |
| All-time low | $2.7352 (May 22, 2024) |
| 52-week high | $2.8775 |
| 52-week low | $2.8775 |
| Median price | $3.0181 |
| Average price | $3.9893 |
| Largest weekly change | -36.0% (Apr 17, 2024) |
| Weeks tracked | 165 |
| Tracking since | Dec 21, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
-48.0%
5Y
N/A
All
-42.1%
Last surveyed Feb 11, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE ER 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE ER 30 MG CAP, manufactured by Rhodes Pharmaceuticals L.P., is $2.8775 per EA (NDC 42858007845), effective Feb 11, 2026.
How has the price of METHYLPHENIDATE ER 30 MG CAP changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE ER 30 MG CAP has declined 42.1%. It has been tracked across 165 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE ER 30 MG CAP?
Since Dec 21, 2022, the NADAC for METHYLPHENIDATE ER 30 MG CAP has ranged from a low of $2.7352 (May 22, 2024) to a high of $5.5319 (Apr 10, 2024), with a median of $3.0181 per EA.
Are there cheaper alternatives to METHYLPHENIDATE ER 30 MG CAP?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE ER(CD) 30 MG CP, is $1.8984 per EA — about 34% below METHYLPHENIDATE ER 30 MG CAP.
Who manufactures METHYLPHENIDATE ER 30 MG CAP?
METHYLPHENIDATE ER 30 MG CAP (NDC 42858007845) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.